TBI-0301
- Generic Name
- TBI-0301
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
Phase 2
- Conditions
- Prostate CancerHigh-risk Prostate Cancer
- Interventions
- Radiation: Brachytherapy, External beam radiotherapyProcedure: Radical prostatectomy
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 60
- Registration Number
- NCT03541928
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath